News | Radiation Oncology | March 02, 2023

Ascelia Pharma has announced the successful completion of patient enrollment in its pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance, the company’s novel MRI contrast agent for patients with impaired kidney function.

Ascelia Pharma has announced the successful completion of patient enrollment in its pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance, the company’s novel MRI contrast agent for patients with impaired kidney function.

The successful completion of patient enrollment in Ascelia Pharma's pivotal phase 3 clinical study, SPARKLE, has been announced by CEO Magnum Corfitzen. The study involved the lead candidate drug Orviglance, the company’s novel MRI contrast agent for patients with impaired kidney function. Photo courtesy of Ascelia Pharma.


March 2, 2023 —  Ascelia Pharma, a biotech company focused on improving the life of people living with rare cancer conditions, has announced the successful completion of patient enrollment in its pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance, the company’s novel MRI contrast agent for patients with impaired kidney function. This milestone is the latest step towards Orviglance completing the regulatory process and becoming available to patients for whom the use of current gadolinium-based contrast agents increases the risk of the serious and potentially fatal condition Nephrogenic Systemic Fibrosis (NSF).

Ascelia Pharma’s SPARKLE study aims to demonstrate that Orviglance improves the detection and visualization of focal liver lesions, including liver metastases and primary tumors, in patients with severe kidney impairment. The study is the last of nine studies in the extensive clinical development program for Orviglance, which will enable Ascelia Pharma to complete a New Drug Application (NDA) submission to the FDA.

In a statement, the company, based in Malmö, Sweden, noted that Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is the first contrast agent in development for use in liver magnetic resonance imaging (MRI) in patients with severely impaired kidney function.

“We are very pleased to have reached our enrollment target of 80 patients,” said Magnus Corfitzen, CEO of Ascelia Pharma in a statement, adding, “This is a major milestone in the history of Ascelia Pharma and a key step on the journey to making Orviglance available to patients around the world." Corfitzen further noted: "The focus will now switch to the evaluation of MRI images by independent radiologists, as required by regulatory standards, and the headline results from this pivotal study are expected in mid-2023. Based on strong results in earlier clinical studies, we are optimistic of a positive outcome of SPARKLE and look forward to the next steps in bringing Orviglance through the regulatory process and making it available to patients for whom the use of gadolinium-based products may be medically inadvisable."

Ascelia Pharma is a biotech company focused on orphan oncology treatments which develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway, and currently has two drug candidates – Orviglance (previously referred to as Mangoral) and Oncoral – in clinical development. According to the company, Orviglance aims to give cancer patients with poor kidney function access to safe and effective liver imaging to live longer and healthier lives, noting that the unmet need for these patients represents an addressable market potential of USD 500-600 million in the US, Europe and Japan.

More information: http://www.ascelia.com

Related coverage:

Study compares effect of food intake on manganese-based MRI contrast agent absorption

Ascelia Pharma Presents Study Showing Comparable Efficacy of Orviglance Lesion Visualization and Detection to Gadolinium


Related Content

News | Computed Tomography (CT)

SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...

Time August 06, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

In the ever-evolving landscape of medical imaging, computed tomography (CT) stands out as a cornerstone technology ...

Time July 30, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
News | Breast Imaging

July 29, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time July 29, 2024
arrow
News | Artificial Intelligence

July 26, 2024 — GE HealthCare and Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company, announced a strategic ...

Time July 26, 2024
arrow
Feature | Radiology Business | By Christine Book

Across the healthcare industry, and, notably, throughout the radiology community in just the past few years, the focus ...

Time July 26, 2024
arrow
Feature | Mobile C-Arms | By Melinda Taschetta-Millane

Mobile C-arms continue to revolutionize medical imaging, offering versatility, mobility and real-time visualization ...

Time July 26, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
Subscribe Now